other-cancer

Experts call for integrating GLP-1 drugs and bariatric surgery into routine cancer care

Obesity is an established risk factor for at least 13 types of cancer and worsens outcomes for cancer survivors. Despite this, most cancer care doesn't include systematic obesity management. A commentary from obesity and oncology specialists argues that the explosion of effective obesity treatments — particularly GLP-1 receptor agonists (drugs like semaglutide/Ozempic) and bariatric surgery — represents an unprecedented opportunity to improve cancer survivorship outcomes.

The authors argue for integrating these proven obesity interventions into cancer care protocols as standard practice, rather than leaving them to separate clinical pathways. Given that both GLP-1 drugs and bariatric surgery have demonstrated anti-obesity benefits and potential anti-inflammatory and anti-cancer effects, systematic integration could reduce cancer recurrence and improve overall survival.

This is an advocacy piece calling for structural change in how oncology practices manage obesity, not a clinical trial — but it reflects a growing movement in the field.

Key Findings

Obesity is a risk factor for 13+ cancer types and worsens survivorship outcomes
GLP-1 receptor agonists and bariatric surgery are now proven effective obesity treatments
Integration of obesity management into cancer care is described as 'an unprecedented opportunity'
Current practice keeps obesity management and cancer care largely siloed
Expert commentary advocates for systematic, coordinated obesity-cancer care programs

Implications

If widely adopted, integrating obesity treatment into cancer survivorship programs could meaningfully improve long-term outcomes for a large proportion of cancer patients. Health systems should consider developing multidisciplinary teams that include obesity medicine specialists alongside oncologists. This is particularly timely as GLP-1 drug availability increases.

Caveats

This is an opinion/commentary piece, not a clinical study — no new data presented. The specific magnitude of benefit from obesity treatment in cancer survivors still needs prospective clinical trial evidence. Access and cost of GLP-1 medications remain significant barriers. Summary based on abstract only.

Source: MedPage Hematology/Oncology — 2026-04-09

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.